- Home
- CLDX vs BCAT Comparison
CLDX vs BCAT Comparison
Compare CLDX & BCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- BCAT
- Stock Information
- Founded
- CLDX 1983
- BCAT 2020
- Country
- CLDX United States
- BCAT United States
- Employees
- CLDX N/A
- BCAT N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BCAT Finance/Investors Services
- Sector
- CLDX Health Care
- BCAT Finance
- Exchange
- CLDX Nasdaq
- BCAT Nasdaq
- Market Cap
- CLDX 1.8B
- BCAT 1.8B
- IPO Year
- CLDX 2008
- BCAT N/A
- Fundamental
- Price
- CLDX $25.43
- BCAT $15.34
- Analyst Decision
- CLDX Buy
- BCAT
- Analyst Count
- CLDX 7
- BCAT 0
- Target Price
- CLDX $64.83
- BCAT N/A
- AVG Volume (30 Days)
- CLDX 914.2K
- BCAT 308.8K
- Earning Date
- CLDX 02-24-2025
- BCAT 01-01-0001
- Dividend Yield
- CLDX N/A
- BCAT 9.38%
- EPS Growth
- CLDX N/A
- BCAT N/A
- EPS
- CLDX N/A
- BCAT 1.43
- Revenue
- CLDX $9,976,000.00
- BCAT N/A
- Revenue This Year
- CLDX N/A
- BCAT N/A
- Revenue Next Year
- CLDX N/A
- BCAT N/A
- P/E Ratio
- CLDX N/A
- BCAT $11.41
- Revenue Growth
- CLDX 128.55
- BCAT N/A
- 52 Week Low
- CLDX $22.93
- BCAT $13.67
- 52 Week High
- CLDX $53.18
- BCAT $16.38
- Technical
- Relative Strength Index (RSI)
- CLDX 47.58
- BCAT 39.12
- Support Level
- CLDX $24.14
- BCAT $15.00
- Resistance Level
- CLDX $25.83
- BCAT $15.86
- Average True Range (ATR)
- CLDX 1.23
- BCAT 0.29
- MACD
- CLDX 0.02
- BCAT -0.05
- Stochastic Oscillator
- CLDX 48.41
- BCAT 34.48
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.